Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
2.60% $5.14
America/New_York / 28 mar 2024 @ 09:55
FUNDAMENTALS | |
---|---|
MarketCap: | 250.07 mill |
EPS: | -1.340 |
P/E: | -3.84 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 48.65 mill |
Avg Daily Volume: | 3.12 mill |
RATING 2024-03-27 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | |||
Ebit | ||||||
Asset | ||||||
Debt | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.84 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.65x |
Company: PE -3.84 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.561 (-89.09%) $-4.58 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 4.59 - 5.65 ( +/- 10.31%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-16 | Ferra Joseph J Jr | Buy | 12 562 | Common Stock |
2024-03-16 | Ferra Joseph J Jr | Sell | 4 773 | Common Stock |
2024-03-16 | Ferra Joseph J Jr | Sell | 12 562 | Restricted Stock Unit |
2024-02-29 | Sandler Alan B. | Buy | 55 000 | Stock Option (Right to Buy) |
2024-02-29 | Cherrington Julie M | Buy | 55 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
71.65 |
Last 96 transactions |
Buy: 15 904 291 | Sell: 39 693 676 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $5.14 (2.60% ) |
Volume | 0.0514 mill |
Avg. Vol. | 3.12 mill |
% of Avg. Vol | 1.646 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.97 | N/A | Active |
---|
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.